GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Graphite Bio Inc (NAS:GRPH) » Definitions » EV-to-EBIT

Graphite Bio (Graphite Bio) EV-to-EBIT : -15.22 (As of May. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Graphite Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Graphite Bio's Enterprise Value is $1,112.46 Mil. Graphite Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-73.11 Mil. Therefore, Graphite Bio's EV-to-EBIT for today is -15.22.

The historical rank and industry rank for Graphite Bio's EV-to-EBIT or its related term are showing as below:

GRPH' s EV-to-EBIT Range Over the Past 10 Years
Min: -86.26   Med: 0   Max: 3.39
Current: -15.22

During the past 5 years, the highest EV-to-EBIT of Graphite Bio was 3.39. The lowest was -86.26. And the median was 0.00.

GRPH's EV-to-EBIT is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs GRPH: -15.22

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Graphite Bio's Enterprise Value for the quarter that ended in Dec. 2023 was $879.98 Mil. Graphite Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-73.11 Mil. Graphite Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -8.31%.


Graphite Bio EV-to-EBIT Historical Data

The historical data trend for Graphite Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Graphite Bio EV-to-EBIT Chart

Graphite Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -77.46 -10.32 -12.04

Graphite Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.32 -7.13 -8.82 -9.68 -12.04

Competitive Comparison of Graphite Bio's EV-to-EBIT

For the Biotechnology subindustry, Graphite Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Graphite Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Graphite Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Graphite Bio's EV-to-EBIT falls into.



Graphite Bio EV-to-EBIT Calculation

Graphite Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1112.457/-73.11
=-15.22

Graphite Bio's current Enterprise Value is $1,112.46 Mil.
Graphite Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Graphite Bio  (NAS:GRPH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Graphite Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-73.11/879.977056
=-8.31 %

Graphite Bio's Enterprise Value for the quarter that ended in Dec. 2023 was $879.98 Mil.
Graphite Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Graphite Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Graphite Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Graphite Bio (Graphite Bio) Business Description

Traded in Other Exchanges
N/A
Address
201 Haskins Way, Suite 210, South San Francisco, CA, USA, 94080
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Executives
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Samsara Biocapital, L.p. 10 percent owner 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Phil Gutry officer: CHIEF BUSINESS OFFICER 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Alethia Young officer: Chief Financial Officer C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Versant Ventures Vi Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Matthew Porteus director C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Katherine V Stultz officer: CHIEF OPERATING OFFICER C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Abraham Bassan director C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
L.p. 436, 10 percent owner 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Versant Vantage Ii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rizzuto Carlo director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Smital Shah director C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080